Navigation Links
Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
Date:4/18/2011

HAYWARD, Calif., April 18, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that enrollment in the Phase 3 VISTA-16 study of varespladib in Acute Coronary Syndromes (ACS) will continue based on the positive outcome of an interim biomarker analysis and review of available patient safety data.

An independent statistician completed an analysis of various biomarkers of cardiovascular risk and determined that treatment with once-daily varespladib met the pre-specified criteria for the study to proceed.  The analysis required patients on varespladib to demonstrate pre-defined treatment effects versus placebo at relevant time points on a collection of biomarkers including:  secretory phospholipase A2 (sPLA2), low density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), interleukin-6 (IL-6), and a composite responder endpoint defined as patients achieving LDL-C less than 70 mg/dL and CRP below 1.0 mg/L.  

In parallel with the biomarker analysis, the VISTA-16 independent Data Safety and Monitoring Board (DSMB) completed a review of the available safety database including all reported adverse events and serious adverse events and recommended the continuation of the VISTA-16 clinical study without modification.  This represents the third meeting of DSMB since the start of the study.

"We continue to believe that positive changes in patient biomarkers similar to changes seen in the FRANCIS Phase 2 clinical study will correlate to a reduction in major adverse cardiovascular events in patients treated with varespladib for 16 weeks," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "We are hopeful this approach will eventually prove that rapid and safe reduction of inflammation
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
2. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
3. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
4. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
5. Anthera Announces Update Call Regarding Vial Problems
6. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
7. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
8. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
9. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
10. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
11. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ST. LOUIS , July 11, 2014 ... medical device company, announced today the positive, ... of its innovative SPiNPerc™ procedure. The SPiNPerc ... use of a percutaneous approach to biopsy ... possible.  Hospitals, patients and physicians experience positive ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Inc. (Nasdaq: SVNT ) today announced that its ... by the U.S. Food and Drug Administration (FDA), a strategic ... in a sale of the Company at this time. The ... to the Company to maximize value. The ...
... HATBORO, Pa., Oct. 25 InfoLogix, Inc. ... provider of enterprise mobility solutions for the healthcare and ... at the South Florida Healthcare Trade Faire and Regional ... October 28, 2010 at the Signature Grand Hotel in ...
Cached Medicine Technology:Savient Pharmaceuticals Provides Update on Strategic Alternatives Process 2Savient Pharmaceuticals Provides Update on Strategic Alternatives Process 3InfoLogix to Present at South Florida Healthcare Trade Faire & Regional Conference 2
(Date:7/12/2014)... Burn injuries increase in the summer as people gather around ... those most vulnerable to these seasonal fire hazards: children. ... burned by putting their hands on the side of cooking ... at Loyola University Medical Center in Maywood, Ill., said in ... you play with fire, you get burned, is true -- ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Doylestown Hospital ... a variety of men’s health questions. Paddock tackles ... to men, why women live longer than men, and ... Men's Health Made Simple featured on Doylestown Hospital’s ... a hernia at any age. If you notice pain, ...
(Date:7/12/2014)... Praeclarus Press is excited to offer ... resource for women in need of lactation support. Statistics ... from their children. Today’s mothers receive very clear messages ... often feel unsupported when it comes to balancing working ... insights, and written by Nancy Mohrbacher, an international breastfeeding ...
(Date:7/12/2014)... The largest pure occupational medicine company ... announce that it will be opening its fifth Georgia ... join four Atlanta-based Nova Medical Centers’ locations. The ... Bridge Road, and will be open from 8:30 a.m. ... Nova’s treatment philosophy of rapid return-to-work and decreased treatment ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2
... ethnic disparities remain a challenge for patients in the ... (ACP) said in an updated paper released today. ... an update to a policy paper that was originally ... the gap between racial and ethnic minority patients and ...
... bioGUNE and led by Dr. Aitor Hierro, have opened ... of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), ... of the National Academy of Sciences of the ... possibility of research in humans to detect this pathology ...
... July 26, 2010 The Marilyn B. Gula ... breast cancer with a $50,000 donation to the Phoenix-based ... over two years of $300,000. In addition, the ... to Ohio,s University Hospitals (UH) Ireland Cancer Center, bringing ...
... cardiopulmonary bypass (CPB) during surgery for less complicated ... any impairments in neurocognitive abilities, such as intelligence, ... from The Children,s Hospital of Philadelphia, in a ... , reported on neuropsychological effects after surgery for ...
... Researchers at the University of California, San Diego School ... molecule common to chimpanzees, gorillas and other mammals but ... in some people, likely worsening conditions in which chronic ... acid sugar is an ingredient in some biotechnology drugs, ...
... By Suzanne Robitaille HealthDay Reporter , FRIDAY, July ... the 20th anniversary of the Americans with Disabilities Act on ... made meaningful progress in improving the quality of life for ... exist between the 54 million Americans with disabilities and those ...
Cached Medicine News:Health News:Disparities remain a challenge in health care says American College of Physicians 2Health News:New approach which can help to predict neurodegenerative diseases 2Health News:New approach which can help to predict neurodegenerative diseases 3Health News:The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen 2Health News:Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children 2Health News:Non-human sugar in biotech drugs causes inflammation 2Health News:Non-human sugar in biotech drugs causes inflammation 3Health News:Americans With Disabilities Act Reaches 20th Anniversary 2Health News:Americans With Disabilities Act Reaches 20th Anniversary 3Health News:Americans With Disabilities Act Reaches 20th Anniversary 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: